Finally the dates for the Xarelto bellwether trials have been set. The Xarelto litigation keeps on growing as new lawsuits are filed every day, the latest one from a widow in Florida who claims that Xarelto medication caused her husband’s untimely death because of a fatal internal bleeding. Although the litigation is still on the pretrial stages, the dates have been pushed several times already. This time though the dates for the first two trials have been finally set on February 6, 2017 and March 13, 2017 by presiding United States District Court Judge Eldon Fallon.
The Multi District Litigation has been consolidated in the US District Court for the Eastern District of Louisiana, although the third trial has been scheduled in Mississippi on April 24, 2017, and the fourth on May 30, 2017 in Texas. Due to the large amount of lawsuits that have been filed so far, only these four cases will be heard during the bellwether trials. These specific Xarelto lawsuits have been chosen as the most representative cases.
The manufacturers of Xarelto, Janssen Pharmaceuticals, a subdivision of Johnson&Johnson, and Bayer AG will be the defendants in the Xarelto MDL. The plaintiffs accusation points towards the alleged negligence of the pharmaceutical companies that didn’t properly warn their consumers about the purported dangers of the blood-thinning medication. Xarelto side effects do include uncontrollable internal bleeding episodes that may eventually led to a patient’s death, as there’s no antidote available to reverse the medication’s effects. Xarelto manufacturers knew about the risks of releasing the drug in the market without antidote, yet they still marketed it anyway, advertising it as a safer drug than its competitors.
Since the MDL was consolidated in December 2014, several Xarelto lawsuits have been filed suing the manufacturers for many tipes of damages including pain and suffering, costs of medical treatment, loss of wages and future income, and even funeral costs and burial expenses suffered by the surviving relatives.